One Capital Management LLC grew its position in Bristol-Myers Squibb Company (NYSE:BMY) by 67.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,514 shares of the biopharmaceutical company’s stock after acquiring an additional 15,453 shares during the period. One Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $2,146,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of BMY. State Street Corp boosted its holdings in Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after buying an additional 1,223,457 shares in the last quarter. Jennison Associates LLC boosted its holdings in Bristol-Myers Squibb by 5.4% during the second quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after buying an additional 1,184,652 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after buying an additional 2,451,390 shares in the last quarter. Legal & General Group Plc boosted its holdings in Bristol-Myers Squibb by 2.7% during the second quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock worth $469,802,000 after buying an additional 217,920 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after buying an additional 1,267,900 shares in the last quarter. 69.51% of the stock is currently owned by institutional investors and hedge funds.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.23% of the company’s stock.
BMY has been the topic of a number of research analyst reports. UBS AG reissued a “buy” rating and set a $72.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price objective on the stock in a report on Monday, October 9th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. BMO Capital Markets reissued a “sell” rating and set a $49.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 4th. Finally, Citigroup Inc. boosted their price objective on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $64.93.
Bristol-Myers Squibb Company (BMY) opened at $60.99 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The firm has a market cap of $99,609.57, a P/E ratio of 20.56, a PEG ratio of 2.40 and a beta of 1.18. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period last year, the company posted $0.77 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.56%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 61.42%.
TRADEMARK VIOLATION NOTICE: This article was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.truebluetribune.com/2017/11/14/one-capital-management-llc-purchases-15453-shares-of-bristol-myers-squibb-company-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.